Eli Lilly and Company $LLY Shares Acquired by Cumberland Partners Ltd

Key Points

• Cumberland Partners Ltd increased its Eli Lilly stake by 6.2% in the first quarter, buying 2,110 more shares and bringing its total holdings to 36,235 shares valued at about $33.3 million.
• Eli Lilly reported stronger-than-expected Q1 results, with EPS of $8.55 and revenue of $19.80 billion, both above analyst estimates, while revenue jumped 55.5% year over year.
• The company also announced a quarterly dividend of $1.73 per share and has drawn mixed-but-generally bullish analyst sentiment, with a consensus Moderate Buy rating and price target of $1,283.64.

Cumberland Partners Ltd lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 6.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 36,235 shares of the company's stock after acquiring an additional 2,110 shares during the period. Eli Lilly and Company accounts for about 2.5% of Cumberland Partners Ltd's holdings, making the stock its 12th biggest position. Cumberland Partners Ltd's holdings in Eli Lilly and Company were worth $33,328,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Dempze Nancy E boosted its stake in Eli Lilly and Company by 2.5% during the 1st quarter. Dempze Nancy E now owns 5,631 shares of the company's stock worth $5,179,000 after purchasing an additional 140 shares during the period. Entropy Technologies LP purchased a new stake in shares of Eli Lilly and Company in the first quarter valued at about $10,163,000. Sustainable Insight Capital Management LLC raised its holdings in shares of Eli Lilly and Company by 18.3% in the first quarter. Sustainable Insight Capital Management LLC now owns 16,781 shares of the company's stock valued at $15,435,000 after buying an additional 2,600 shares during the last quarter. Bridgewater Advisors Inc. boosted its stake in shares of Eli Lilly and Company by 2.8% during the first quarter. Bridgewater Advisors Inc. now owns 4,051 shares of the company's stock worth $4,115,000 after buying an additional 110 shares during the period. Finally, Sentinel Advisory Group LLC purchased a new position in shares of Eli Lilly and Company during the first quarter worth about $366,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of LLY opened at $1,196.18 on Friday. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The stock's 50 day moving average is $1,136.56 and its two-hundred day moving average is $1,040.15. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,249.45. The firm has a market capitalization of $1.13 trillion, a PE ratio of 42.49, a P/E/G ratio of 1.50 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company's revenue for the quarter was up 55.5% on a year-over-year basis. During the same period in the prior year, the business posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Research analysts anticipate that Eli Lilly and Company will post 34.21 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company's dividend payout ratio (DPR) is 24.58%.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on LLY. Barclays boosted their price target on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an "overweight" rating in a research report on Monday, May 4th. Guggenheim boosted their target price on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a "buy" rating in a report on Monday, July 13th. Berenberg Bank upped their price target on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a "hold" rating in a research note on Monday, June 22nd. Leerink Partners increased their price target on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an "outperform" rating in a report on Thursday, June 25th. Finally, BMO Capital Markets reiterated an "outperform" rating on shares of Eli Lilly and Company in a research report on Monday, June 15th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Eli Lilly and Company has a consensus rating of "Moderate Buy" and a consensus price target of $1,283.64.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly reported strong late-stage results for retatrutide, its next-generation obesity drug, in two Phase 3 trials. The drug met its primary endpoint and produced substantial weight loss and A1C improvement, reinforcing expectations for a major future growth franchise. Article Title
• Positive Sentiment: The company said it now plans to file for FDA approval of retatrutide in Q1 2027, keeping the drug on a path toward commercialization and supporting the long-term growth outlook for LLY. Article Title
• Positive Sentiment: A Lilly-backed biotech, Scribe Therapeutics, priced an upsized IPO with strong demand, highlighting continued investor appetite for Lilly-associated pipeline assets and partnerships. Article Title
• Neutral Sentiment: Healthcare stocks were broadly higher late Friday, which may be lending general support to Eli Lilly’s shares. Article Title
• Negative Sentiment: Novo Nordisk is seeking a preliminary injunction to block Lilly’s weight-loss and diabetes ads, accusing the company of using outdated data and misleading comparisons versus Wegovy and Ozempic. That raises legal and regulatory risk for Eli Lilly, even if the impact is likely more headline-driven than fundamental for now. Article Title

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.